Category Medicine and Healthcare

Key FDA Marijuana Response, MMJ International Holdings Advances Cannabis-Derived Therapeutics for Huntington’s Disease
Press Release

Key FDA Marijuana Response, MMJ International Holdings Advances Cannabis-Derived Therapeutics for Huntington’s Disease

MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has obstructed domestic cannabis research despite the Right To Try and the Medical Marijuana Research Expansion Act. MMJ accuses the DEA of bias in restricting MMJ to cultivate its proprietary marijuana cultivars necessary for research and pharmaceutical drug manufacturing. A pending federal court ruling in Rhode Island will set a significant precedent, challenging DEA authority and potentially easing regulatory barriers for MMJ's future cannabinoid drug development.

MEET DEA DIVERSION Thomas Prevoznik - The man behind the DEA marijuana scam- He Defied Presidential Mandates on Cannabis Research and Right to Try 

Read More
Press Release

Notice of Data Breach

Read More
Press Release

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Trial taking place at Sheikh Khalifa Medical City, a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi

Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID

Proof-of-concept (POC) data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for these rare/orphan diseases

Read More